Literature DB >> 11384101

p53 mutations in urinary bladder cancer.

P Berggren1, G Steineck, J Adolfsson, J Hansson, O Jansson, P Larsson, B Sandstedt, H Wijkström, K Hemminki.   

Abstract

We have screened for mutations in exons 5-8 of the p53 gene in a series consisting of 189 patients with urinary bladder neoplasms. 82 (44%) neoplasms were lowly malignant (Ta, G1-G2a) and 106 (56%) were highly malignant (G2b-G4 or > or = T1). Only one mutation was in a lowly malignant urinary bladder neoplasm, in total we found p53 mutations in 26 (14%) of the 189 patients. 30% of the samples had loss of heterozygosity (LOH) for one or both of the p53 exogenic (CA)n repeat and the p53 intragenic (AAAAT)n repeat markers. 31 samples (21%) showed LOH but were not mutated, suggesting other mechanisms inactivating p53 than mutations. 4 mutations were found at codon 280 and 2 mutations were found at codon 285, 2 previously reported hot spots for urinary bladder cancer. The study indicate a boundary between G2a and G2b tumours concerning the occurrence of genetic events affecting p53 function; moderately differentiated (G2) urinary bladder neoplasms probably are genetically heterogeneous which supports the suggestion that they should not be grouped together but instead, for example, be categorized as either lowly or highly malignant. Copyright 2001 Cancer Research Campaign.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11384101      PMCID: PMC2363660          DOI: 10.1054/bjoc.2001.1823

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  47 in total

Review 1.  The genetics of transitional cell carcinoma: progress and potential clinical application.

Authors:  M A Knowles
Journal:  BJU Int       Date:  1999-09       Impact factor: 5.588

Review 2.  Identification of novel bladder tumour suppressor genes.

Authors:  M A Knowles
Journal:  Electrophoresis       Date:  1999-02       Impact factor: 3.535

3.  Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in myeloid crisis harboring loss of a chromosome 17p.

Authors:  H Nakai; S Misawa; J Toguchida; D W Yandell; K Ishizaki
Journal:  Cancer Res       Date:  1992-12-01       Impact factor: 12.701

Review 4.  The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee.

Authors:  J I Epstein; M B Amin; V R Reuter; F K Mostofi
Journal:  Am J Surg Pathol       Date:  1998-12       Impact factor: 6.394

Review 5.  Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer.

Authors:  W P Bennett; S P Hussain; K H Vahakangas; M A Khan; P G Shields; C C Harris
Journal:  J Pathol       Date:  1999-01       Impact factor: 7.996

6.  IARC Database of p53 gene mutations in human tumors and cell lines: updated compilation, revised formats and new visualisation tools.

Authors:  P Hainaut; T Hernandez; A Robinson; P Rodriguez-Tome; T Flores; M Hollstein; C C Harris; R Montesano
Journal:  Nucleic Acids Res       Date:  1998-01-01       Impact factor: 16.971

Review 7.  Li-Fraumeni syndrome--a molecular and clinical review.

Authors:  J M Varley; D G Evans; J M Birch
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

8.  p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3.

Authors:  M M Wales; M A Biel; W el Deiry; B D Nelkin; J P Issa; W K Cavenee; S J Kuerbitz; S B Baylin
Journal:  Nat Med       Date:  1995-06       Impact factor: 53.440

Review 9.  On the origins of tumor mutations in cancer genes: insights from the p53 gene.

Authors:  M Hollstein; G Moeckel; M Hergenhahn; B Spiegelhalder; M Keil; G Werle-Schneider; H Bartsch; J Brickmann
Journal:  Mutat Res       Date:  1998-09-20       Impact factor: 2.433

10.  Carcinomas of the renal pelvis associated with smoking and phenacetin abuse: p53 mutations and polymorphism of carcinogen-metabolising enzymes.

Authors:  P P Bringuier; M McCredie; G Sauter; M Bilous; J Stewart; M J Mihatsch; P Kleihues; H Ohgaki
Journal:  Int J Cancer       Date:  1998-10-23       Impact factor: 7.396

View more
  15 in total

1.  Genetic polymorphisms in the DNA repair genes XPD and XRCC1, p53 gene mutations and bladder cancer risk.

Authors:  Weimin Gao; Marjorie Romkes; Shilong Zhong; Tomoko Nukui; Raj A Persad; Patrick J B Smith; Robert Branch; Phouthone Keohavong
Journal:  Oncol Rep       Date:  2010-07       Impact factor: 3.906

2.  Investigation of the association between mitochondrial DNA and p53 gene mutations in transitional cell carcinoma of the bladder.

Authors:  Tuba Avcilar; Deniz Kirac; Deniz Ergec; Gulsah Koc; Korkut Ulucan; Zehra Kaya; Elif Cigdem Kaspar; Levent Turkeri; Ahmet Ilter Guney
Journal:  Oncol Lett       Date:  2016-08-11       Impact factor: 2.967

3.  UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer.

Authors:  M Unoki; J D Kelly; D E Neal; B A J Ponder; Y Nakamura; R Hamamoto
Journal:  Br J Cancer       Date:  2009-06-02       Impact factor: 7.640

4.  P53 mutations in urinary bladder cancer patients from Central Poland.

Authors:  Edyta Borkowska; Aleksandra Binka-Kowalska; Maria Constantinou; Agnieszka Nawrocka; Józef Matych; Bogdan Kałuzewski
Journal:  J Appl Genet       Date:  2007       Impact factor: 3.240

5.  The expression of PAX5, p53 immunohistochemistry and p53 mutation analysis in superficial bladder carcinoma tissue. Correlation with pathological findings and clinical outcome.

Authors:  M Babjuk; V Soukup; J Mares; J Dusková; Z Sedlácek; M Trková; L Pecen; J Dvorácek; T Hanus; R Kocvara; J Novák; C Povýsil
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

6.  TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism.

Authors:  P Sivaramakrishna Rachakonda; Ismail Hosen; Petra J de Verdier; Mahdi Fallah; Barbara Heidenreich; Charlotta Ryk; N Peter Wiklund; Gunnar Steineck; Dirk Schadendorf; Kari Hemminki; Rajiv Kumar
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-07       Impact factor: 11.205

7.  Radiation induces p53-dependent cell apoptosis in bladder cancer cells with wild-type- p53 but not in p53-mutated bladder cancer cells.

Authors:  Nobuyuki Hinata; Toshiro Shirakawa; Zhujun Zhang; Akira Matsumoto; Masato Fujisawa; Hiroshi Okada; Sadao Kamidono; Akinobu Gotoh
Journal:  Urol Res       Date:  2003-09-04

8.  NBN Gene Polymorphisms and Cancer Susceptibility: A Systemic Review.

Authors:  Francesco Berardinelli; Alessandra di Masi; Antonio Antoccia
Journal:  Curr Genomics       Date:  2013-11       Impact factor: 2.236

9.  MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1.

Authors:  Hans Olsson; Per Hultman; Johan Rosell; Peter Söderkvist; Staffan Jahnson
Journal:  BMC Urol       Date:  2013-01-28       Impact factor: 2.264

10.  A population-based study of immunohistochemical detection of p53 alteration in bladder cancer.

Authors:  K T Kelsey; T Hirao; A Schned; S Hirao; T Devi-Ashok; H H Nelson; A Andrew; M R Karagas
Journal:  Br J Cancer       Date:  2004-04-19       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.